Sign up Australia
Proactive Investors - Run By Investors For Investors

The Hydroponics Company recognises value in manufacturing facility

The company now has complete end-to-end growing and manufacturing facilities.
man in white lab coat tending to indoor cannabis farm
To replace the acquired facility would cost an estimated $35 million

The Hydroponics Company Ltd (ASX:THC) has received an independent valuation for its recently acquired pharmaceutical manufacturing facility in Southport, Queensland.

Notably, with land and building at acquisition price, the combined value will be recognised in THC’s June 2018 half-year accounts at $16.68 million.

The facility complements the existing licenced R&D and growing facility in Bundaberg and the 60,000 square metre growing site in northern Queensland.

READ: The Hydroponics Company forms alliance with major European supplier

THC’s chairman Steven Xu said: “Having secured significant medicinal cannabis growing capability and a manufacturing facility with industry leading capacity, THC has a clear path to a revenue generating medicinal cannabis business in the near term, with the ability to service domestic patients and export into other markets.

“Securing key commercial partners from the global medicinal cannabis industry such as Endoca, BOL Pharma, and Ascent places THC in prime position to take advantage of its production-ready capabilities.

“The increase in shareholder value from the acquisition of THC’s Southport manufacturing facility highlights THC’s prudent investment and corporate strategy.”

Attractive to global commercial partners

THC’s vertically integrated supply strategy provides a platform for international market access that is attractive to global commercial partners.

The company now has complete end-to-end growing and manufacturing facilities capable of large-scale operation to produce pharma-grade medicinal cannabis products.

READ: The Hydroponics Company growing vertically integrated business in medicinal cannabis industry

THC continues to attract, engage and retain global partners such as Endoca (Europe), BOL Pharma (Israel), and Ascent Industries (North America).

View full THC profile View Profile

The Hydroponics Company Timeline

Related Articles

Dog skeleton with cannabis plant leaf
Tue
The company's lead drug candidate is a cannabis-derived canine pain medication.
Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.
1521490126_shutterstock_234586750.jpg
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use